EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSSAUG00010018578
Gene Symbol: KCNQ5
1 Cross references
196 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSSAUG00010024701
Gene Symbol: KCNQ2A
1 Cross references
185 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSSAUG00010021421
Gene Symbol: PSENEN
3 Cross references
183 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSSAUG00010020771
Gene Symbol: LOC115565907
3 Cross references
200 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSSAUG00010011101
Gene Symbol: LOC115585944
3 Cross references
205 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSSAUG00010015263
Gene Symbol: LOC115566005
3 Cross references
255 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSSAUG00010008872
Gene Symbol: LOC115578932
3 Cross references
250 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSSAUG00010023099
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSSAUG00010022751
Gene Symbol: PTGDR2
1 Cross references
135 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSSAUG00010026167
Gene Symbol: PTGDR2
3 Cross references
145 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSSAUG00010027498
Gene Symbol: PTGER3
3 Cross references
194 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSAUG00010022081
Gene Symbol: LOC115579386
3 Cross references
167 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).